After nearly a decade of litigation, Novartis Pharmaceuticals Corp. (Novartis) has agreed to pay over $678 million in separate settlements to resolve claims that it systematically violated the federal False Claims Act and the Anti-Kickback Statute after the company spent more than $100 million on lavish meals, fishing junkets, golf outings, wine tastings, sporting events and speaker fees to influence thousands of doctors to prescribe its medicines.
The settlement resolves the lawsuit captioned Bilotta v. Novartis Pharmaceuticals, No. 1:11-cv-0071-PCG (S.D.N.Y.) initially filed in 2011 by a former Novartis sales representative under the private whistleblower provisions of the False Claims Act, which permits private parties to file suit on behalf of the United States for false claims and share in a portion of the government’s recovery. The U.S. government joined the civil suit in 2013.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]